Ikerchem offers two promising anticancer drugs with best in class attributes available for in licensing.
If you are interested in acquiring or co-developing oncology products with excellent solid tumor activity
and optimum safety profile, please, read the offer below.
IKH02 is currently at the late preclinical stage and is a novel oral HDAC pan-inhibitor with amazing toxicological/safety
profile and excellent PK/activity data. No/little side effects are expected to occur in clinical phases, while real responses
in solid and hematologic tumors are foreseen. IND filing is expected for Q1 2012.
IKH25 is a hundred-fold selective HDAC6 inhibitor, whose IND filing is expected for Q4 2012.
Great activity in solid tumors has been observed. This compound showed excellent PK, toxicity and activity profiles.
Ikerchem is also developing best in class DNMT, Proteasome and JMJ inhibitors, which are now at the lead optimization stage.
For more information please contact me at:
|Pharma licensing||Out-licensing (offer)|